The most common treatments for atrial fibrillation (AFib) are blood thinners to prevent stroke and medications to control heart rate or rhythm. Nearly every person diagnosed with AFib will be started on at least one of these, and many will use a combination. The specific mix depends on how often episodes occur, how severe symptoms are, and whether other heart conditions are present.
Blood Thinners: The First Priority
AFib causes the upper chambers of the heart to quiver instead of contracting fully, which lets blood pool and form clots. Those clots can travel to the brain and cause a stroke. Preventing that is the single most important part of AFib treatment, and it starts before anything else.
Doctors use a scoring system called CHA₂DS₂-VASc to estimate your stroke risk based on factors like age, sex, history of heart failure, high blood pressure, diabetes, and prior stroke. Men with a score of 2 or higher (3 or higher for women) should be on anticoagulation. Men scoring 1 and women scoring 2 fall into a gray zone where it may be considered based on individual risk factors. Scores of 0 for men or 1 for women generally don’t need blood thinners.
The preferred blood thinners today are direct oral anticoagulants, commonly called DOACs. Four are approved for AFib: apixaban, rivaroxaban, dabigatran, and edoxaban. These have largely replaced warfarin because they work at least as well, cause fewer dangerous bleeding events, and don’t require the regular blood tests that warfarin demands. Warfarin is still used in certain situations, particularly for people with mechanical heart valves or severe mitral valve disease, but DOACs are the default for most patients.
Bleeding risk doesn’t automatically rule out blood thinners. A separate scoring tool called HAS-BLED helps identify factors that raise bleeding risk, including uncontrolled high blood pressure, kidney or liver problems, prior bleeding episodes, age 65 and older, and regular alcohol use. A high score (3 or above) doesn’t mean you stop anticoagulation. It means your doctor should look for reversible risk factors, like switching medications that increase bleeding or getting blood pressure under control, and monitor you more closely.
Rate Control: Slowing the Heart
Rate control is the most widely used strategy for managing AFib symptoms. The goal is simple: slow the heart rate to a more comfortable range so you feel better, even though the irregular rhythm itself continues. For many people with mild or tolerable symptoms, this is all that’s needed beyond blood thinners.
Beta-blockers are the most commonly prescribed rate control drugs. Metoprolol is a typical first choice, taken once or twice daily depending on the formulation. Atenolol and carvedilol are other options. These work by blocking the signals that speed up your heart, bringing the rate down during both rest and activity.
Calcium channel blockers like diltiazem and verapamil are alternatives, particularly for people who can’t tolerate beta-blockers. They slow heart rate through a different mechanism and are effective, but they’re not safe for people with heart failure and reduced pumping strength. Beta-blockers and calcium channel blockers are not typically combined because the effect on heart rate can be too aggressive.
Rate control is often the starting point because the medications are well-tolerated, widely available, and effective for symptom relief. But it doesn’t address the underlying rhythm problem, and some people continue to feel fatigued, short of breath, or limited in their daily activities despite a controlled rate.
Rhythm Control: Restoring Normal Heartbeat
Rhythm control aims to restore and maintain the heart’s normal sinus rhythm. Current guidelines emphasize early rhythm control, meaning treatment should focus on getting the heart back into a normal rhythm sooner rather than waiting to see if rate control alone is enough. This represents a shift from older approaches that treated rate and rhythm control as roughly equal options.
Antiarrhythmic medications are one way to maintain normal rhythm. Flecainide and propafenone work well for people whose hearts are structurally normal, with no history of heart attack or heart failure. They’re effective but carry real risks for patients with underlying heart disease. A landmark set of trials showed increased mortality when these drugs were used in people with prior heart attacks, so they’re reserved for patients without structural heart problems.
Amiodarone is the most broadly applicable antiarrhythmic and can be used even in patients with heart failure. It’s effective at maintaining normal rhythm, but long-term use comes with a unique set of concerns: it can affect the thyroid, lungs, liver, and eyes, so patients on amiodarone need regular monitoring. Sotalol is another option that combines rhythm control with heart rate slowing properties, though it requires kidney function above a certain threshold and cardiac monitoring when first started due to a small risk of a dangerous rhythm disturbance.
Catheter Ablation: A Procedure-Based Option
Catheter ablation has become one of the most important treatments for AFib. The procedure involves threading thin, flexible tubes through a vein (usually in the groin) into the heart, then using energy to create small scars around the pulmonary veins. These veins are where most of the erratic electrical signals originate, and scarring the tissue around them blocks those signals from reaching the rest of the heart.
The latest guidelines give catheter ablation a top-tier recommendation as first-line therapy in selected patients, meaning it can now be offered before trying medications. This upgrade reflects consistent evidence that ablation outperforms antiarrhythmic drugs at maintaining normal rhythm. For people with heart failure and reduced pumping function, ablation also carries a strong recommendation because it’s been shown to improve heart function in ways that drugs alone often don’t.
Success rates depend on the type of AFib. For paroxysmal AFib (episodes that come and go), a single procedure keeps about 69% of patients in normal rhythm at one year and roughly 62% at five years. For persistent AFib (episodes lasting longer than seven days), the numbers are lower: around 51% at one year and 42% at three years after a single procedure. Many patients undergo a second procedure, which improves those numbers considerably. One study following patients who had repeat procedures as needed found 85% were free of AFib at three years and 71% at five years.
Pulsed Field Ablation
A newer form of ablation called pulsed field ablation (PFA) uses rapid electrical pulses instead of heat or cold to disable heart tissue. A meta-analysis of six studies involving nearly 2,000 patients found that PFA reduced AFib recurrence by about 33% compared to traditional thermal ablation. Procedures were roughly 21 minutes shorter. Perhaps most notably, PFA was safer for surrounding structures: esophageal injuries occurred only in the traditional ablation group (10 cases versus zero), and nerve damage to the diaphragm was significantly less common. Rates of stroke and serious complications like cardiac perforation were similar between the two approaches.
Left Atrial Appendage Closure
For patients who need stroke protection but can’t safely take blood thinners long-term, a small implanted device can seal off the left atrial appendage, a small pouch in the heart where most AFib-related clots form. The most widely known device is the Watchman. It’s placed through a catheter procedure similar to ablation.
This option is approved for people at elevated stroke risk who have a legitimate reason to avoid long-term anticoagulation. In practice, the most common reasons are a history of major bleeding (reported in about 64% of cases in a large U.S. registry), high fall risk (36%), and difficulty maintaining stable blood thinner levels. It’s not a first-line alternative to blood thinners for most people, but it fills an important gap for those who truly can’t take them.
Weight Loss and Lifestyle Changes
Lifestyle modification is increasingly recognized as a core part of AFib treatment, not just a nice addition. Obesity, high blood pressure, sleep apnea, diabetes, and heavy alcohol use all independently increase AFib risk and make existing AFib harder to control.
Weight loss has some of the strongest evidence. Patients who lost 10% or more of their body weight had six times the likelihood of remaining free from arrhythmia compared to those who lost less or maintained their weight. Among people who were obese but brought their BMI below 30 within five years, AFib risk dropped to levels comparable to people who had never been obese. After ablation, weight loss of 10% or more before or after the procedure was associated with lower recurrence rates, particularly for people with persistent AFib and a shorter AFib history.
A structured approach combining weight management with blood pressure control, better blood sugar regulation, and treatment of sleep apnea has been shown to reduce AFib episode frequency, duration, and symptom severity. These aren’t optional extras. Addressing these risk factors makes every other treatment, whether medications or ablation, work better.